Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006
This article was originally published in The Pink Sheet Daily
Generics firm expects growth from generic Pravachol and generic Zocor exclusivity periods.
You may also be interested in...
Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Watson also enters into the pravastatin market with an authorized generic.